A review on emerging targeted therapies for the management of metastatic colorectal cancers
Colorectal cancers are among the most commonly found cancers over the world. In spite of the recent advancements in diagnosis and prognosis, the management of this metastatic condition remains a challenge. The utility of monoclonal antibodies in the healing of patients with colorectal cancer has ope...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2023-04, Vol.40 (6), p.159-159, Article 159 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 159 |
|---|---|
| container_issue | 6 |
| container_start_page | 159 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 40 |
| creator | Deshmukh, Rohitas Prajapati, Mahendra Harwansh, Ranjit K. |
| description | Colorectal cancers are among the most commonly found cancers over the world. In spite of the recent advancements in diagnosis and prognosis, the management of this metastatic condition remains a challenge. The utility of monoclonal antibodies in the healing of patients with colorectal cancer has opened a new chapter in the quest for newer therapies. The resistance to the standard treatment regimen made it mandatory to search for newer targets. Mutagenic alterations in the gene engaged in cellular differentiation and growth pathway have been the reason for resistance to treatment. The newer therapies target the various proteins and receptors involved in the signal transduction and down streaming pathways leading to cell proliferation. This review presents an insight into the newer targeted therapies for colorectal cancer involving tyrosine kinase blockers, epidermal growth factor receptors, vascular endothelial growth factor, immune checkpoint therapy, and BRAF inhibitors.
Graphical abstract |
| doi_str_mv | 10.1007/s12032-023-02020-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2806072844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2806072844</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-812bccd22b497ed12329d83016fc437dd823711bf73f5ed7c0d80d1b60de2dfd3</originalsourceid><addsrcrecordid>eNp9kMFq3DAQhkVISbabvEAORZBLL25HkrWyjyG0TSGQSwuFHoQsjR0H29pIcrN9-2rrpCk5BDFIg775JT5Czhh8YADqY2QcBC-Ai1x5FbsDsmJS1gUT7Mfhf-dj8jbGOwDOJK-PyLFQUCsBakV-XtCAv3p8oH6iOGLo-qmjyYQOEzqabjGYbY-Rtj7sOzqayXQZnBL1LR0xmZhM6i21fvABbTIDtWayGOIJedOaIeLp474m3z9_-nZ5VVzffPl6eXFdWKFkKirGG2sd501ZK3SMC167SgDbtLYUyrmKC8VY0yrRSnTKgqvAsWYDDrlrnViT90vuNvj7GWPSYx8tDoOZ0M9R8wo2oHhVlhk9f4He-TlM-Xd7SirJQcpM8YWywccYsNXb0I8m_NYM9F69XtTrrF7_Va93eejdY_TcjOj-jTy5zoBYgJivpg7D89uvxP4BiqqPmg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2805752055</pqid></control><display><type>article</type><title>A review on emerging targeted therapies for the management of metastatic colorectal cancers</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Deshmukh, Rohitas ; Prajapati, Mahendra ; Harwansh, Ranjit K.</creator><creatorcontrib>Deshmukh, Rohitas ; Prajapati, Mahendra ; Harwansh, Ranjit K.</creatorcontrib><description>Colorectal cancers are among the most commonly found cancers over the world. In spite of the recent advancements in diagnosis and prognosis, the management of this metastatic condition remains a challenge. The utility of monoclonal antibodies in the healing of patients with colorectal cancer has opened a new chapter in the quest for newer therapies. The resistance to the standard treatment regimen made it mandatory to search for newer targets. Mutagenic alterations in the gene engaged in cellular differentiation and growth pathway have been the reason for resistance to treatment. The newer therapies target the various proteins and receptors involved in the signal transduction and down streaming pathways leading to cell proliferation. This review presents an insight into the newer targeted therapies for colorectal cancer involving tyrosine kinase blockers, epidermal growth factor receptors, vascular endothelial growth factor, immune checkpoint therapy, and BRAF inhibitors.
Graphical abstract</description><identifier>ISSN: 1559-131X</identifier><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-023-02020-x</identifier><identifier>PMID: 37097307</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - therapeutic use ; Cancer therapies ; Cell growth ; Colonic Neoplasms ; Colorectal cancer ; Colorectal Neoplasms - pathology ; ErbB Receptors - genetics ; Fatalities ; Hematology ; Humans ; Internal Medicine ; Kinases ; Medicine ; Medicine & Public Health ; Mutation ; Oncology ; Pathology ; Rectal Neoplasms ; Review Article ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A</subject><ispartof>Medical oncology (Northwood, London, England), 2023-04, Vol.40 (6), p.159-159, Article 159</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-812bccd22b497ed12329d83016fc437dd823711bf73f5ed7c0d80d1b60de2dfd3</citedby><cites>FETCH-LOGICAL-c375t-812bccd22b497ed12329d83016fc437dd823711bf73f5ed7c0d80d1b60de2dfd3</cites><orcidid>0000-0002-8962-6821</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-023-02020-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-023-02020-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37097307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deshmukh, Rohitas</creatorcontrib><creatorcontrib>Prajapati, Mahendra</creatorcontrib><creatorcontrib>Harwansh, Ranjit K.</creatorcontrib><title>A review on emerging targeted therapies for the management of metastatic colorectal cancers</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Colorectal cancers are among the most commonly found cancers over the world. In spite of the recent advancements in diagnosis and prognosis, the management of this metastatic condition remains a challenge. The utility of monoclonal antibodies in the healing of patients with colorectal cancer has opened a new chapter in the quest for newer therapies. The resistance to the standard treatment regimen made it mandatory to search for newer targets. Mutagenic alterations in the gene engaged in cellular differentiation and growth pathway have been the reason for resistance to treatment. The newer therapies target the various proteins and receptors involved in the signal transduction and down streaming pathways leading to cell proliferation. This review presents an insight into the newer targeted therapies for colorectal cancer involving tyrosine kinase blockers, epidermal growth factor receptors, vascular endothelial growth factor, immune checkpoint therapy, and BRAF inhibitors.
Graphical abstract</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Cell growth</subject><subject>Colonic Neoplasms</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - pathology</subject><subject>ErbB Receptors - genetics</subject><subject>Fatalities</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Rectal Neoplasms</subject><subject>Review Article</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A</subject><issn>1559-131X</issn><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kMFq3DAQhkVISbabvEAORZBLL25HkrWyjyG0TSGQSwuFHoQsjR0H29pIcrN9-2rrpCk5BDFIg775JT5Czhh8YADqY2QcBC-Ai1x5FbsDsmJS1gUT7Mfhf-dj8jbGOwDOJK-PyLFQUCsBakV-XtCAv3p8oH6iOGLo-qmjyYQOEzqabjGYbY-Rtj7sOzqayXQZnBL1LR0xmZhM6i21fvABbTIDtWayGOIJedOaIeLp474m3z9_-nZ5VVzffPl6eXFdWKFkKirGG2sd501ZK3SMC167SgDbtLYUyrmKC8VY0yrRSnTKgqvAsWYDDrlrnViT90vuNvj7GWPSYx8tDoOZ0M9R8wo2oHhVlhk9f4He-TlM-Xd7SirJQcpM8YWywccYsNXb0I8m_NYM9F69XtTrrF7_Va93eejdY_TcjOj-jTy5zoBYgJivpg7D89uvxP4BiqqPmg</recordid><startdate>20230425</startdate><enddate>20230425</enddate><creator>Deshmukh, Rohitas</creator><creator>Prajapati, Mahendra</creator><creator>Harwansh, Ranjit K.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8962-6821</orcidid></search><sort><creationdate>20230425</creationdate><title>A review on emerging targeted therapies for the management of metastatic colorectal cancers</title><author>Deshmukh, Rohitas ; Prajapati, Mahendra ; Harwansh, Ranjit K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-812bccd22b497ed12329d83016fc437dd823711bf73f5ed7c0d80d1b60de2dfd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Cell growth</topic><topic>Colonic Neoplasms</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - pathology</topic><topic>ErbB Receptors - genetics</topic><topic>Fatalities</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Rectal Neoplasms</topic><topic>Review Article</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deshmukh, Rohitas</creatorcontrib><creatorcontrib>Prajapati, Mahendra</creatorcontrib><creatorcontrib>Harwansh, Ranjit K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deshmukh, Rohitas</au><au>Prajapati, Mahendra</au><au>Harwansh, Ranjit K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review on emerging targeted therapies for the management of metastatic colorectal cancers</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2023-04-25</date><risdate>2023</risdate><volume>40</volume><issue>6</issue><spage>159</spage><epage>159</epage><pages>159-159</pages><artnum>159</artnum><issn>1559-131X</issn><issn>1357-0560</issn><eissn>1559-131X</eissn><abstract>Colorectal cancers are among the most commonly found cancers over the world. In spite of the recent advancements in diagnosis and prognosis, the management of this metastatic condition remains a challenge. The utility of monoclonal antibodies in the healing of patients with colorectal cancer has opened a new chapter in the quest for newer therapies. The resistance to the standard treatment regimen made it mandatory to search for newer targets. Mutagenic alterations in the gene engaged in cellular differentiation and growth pathway have been the reason for resistance to treatment. The newer therapies target the various proteins and receptors involved in the signal transduction and down streaming pathways leading to cell proliferation. This review presents an insight into the newer targeted therapies for colorectal cancer involving tyrosine kinase blockers, epidermal growth factor receptors, vascular endothelial growth factor, immune checkpoint therapy, and BRAF inhibitors.
Graphical abstract</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37097307</pmid><doi>10.1007/s12032-023-02020-x</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8962-6821</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1559-131X |
| ispartof | Medical oncology (Northwood, London, England), 2023-04, Vol.40 (6), p.159-159, Article 159 |
| issn | 1559-131X 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2806072844 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Cancer therapies Cell growth Colonic Neoplasms Colorectal cancer Colorectal Neoplasms - pathology ErbB Receptors - genetics Fatalities Hematology Humans Internal Medicine Kinases Medicine Medicine & Public Health Mutation Oncology Pathology Rectal Neoplasms Review Article Vascular endothelial growth factor Vascular Endothelial Growth Factor A |
| title | A review on emerging targeted therapies for the management of metastatic colorectal cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T04%3A45%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20on%20emerging%20targeted%20therapies%20for%20the%20management%20of%20metastatic%20colorectal%20cancers&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Deshmukh,%20Rohitas&rft.date=2023-04-25&rft.volume=40&rft.issue=6&rft.spage=159&rft.epage=159&rft.pages=159-159&rft.artnum=159&rft.issn=1559-131X&rft.eissn=1559-131X&rft_id=info:doi/10.1007/s12032-023-02020-x&rft_dat=%3Cproquest_cross%3E2806072844%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2805752055&rft_id=info:pmid/37097307&rfr_iscdi=true |